II. Epidemiology
- Typical onset ages 30-50 years old
- Northern european descent and fair skinned persons
- More common in women by factor of 2-3
- Prevalence: 1.3-2.1% (14 Million cases) in United States
III. Risk Factors: Predisposing triggers and exacerbating factors
- Sun Exposure, hot weather, and hot baths
- Emotional stressors
- Alcohol use
- Hot drinks
- Exercise
- Nose Hair Follicle mites (Demodex folliculorum)
IV. Pathophysiology
- Acneiform eruption
V. Types
- Subtype 1: Erythematotelangiectatic (most difficult to treat)
- Persistent central face Macular erythema with Telangiectasias and Flushing
- Possible ocular involvement
- Subtype 2: Papulopustular (easiest to treat)
- Subtype 3: Phymatous (more common in men)
- Skin thickening and nodular irregularities (due to Sebaceous Gland hyperplasia)
- Distribution: Nose (Rhinophyma), chin, ears, forehead or Eyelid
- Subtype 4: Ocular
- Watery, Bloodshot Eyes may become dry with foreign body Sensation and photophobia
- Distribution: Blepharitis, Conjunctivitis, and Eyelid Inflammation
- Variant: Granulomatous
VI. Symptoms
- Stinging pain may accompany facial Flushing
VII. Signs
- Course is variable
- Stages listed below are for organization only
- Distribution for all lesions
- Affects middle third of face (forehead to chin)
- Stage 1: Initial presentation
- Stage 2: Early vascular changes
- Facial erythema
- Telangiectasis
- Eye changes (see ocular signs below)
- Stage 3: Inflammatory changes
- Stage 4: Rhinophyma (Red bulbous nose)
- More common in men
- Thickening of facial skin (especially nose)
- Connective tissue hypertrophy
- Sebaceous Gland hypertrophy
- Previously thought to be a sign Alcohol Abuse
- Example: W. C. Fields
- Variant: Granulomatous Rosacea
- May appear similar to facial sarcoid
VIII. Signs: Ocular involvement (50% of Rosacea cases)
-
Eyelid Inflammation (may be presenting sign)
- Acne involving Eyelids
- Eyelid redness and swelling
- Eyelid margin Telangiectasia
- Inflammatory Conjunctivitis
- Blepharitis may accompany Conjunctivitis
- Eyes that itch or burn
- Dry Eyes with sandpaper or foreign body Sensation
- Other less common changes
IX. Differential Diagnosis: Skin
- Late-onset Acne Vulgaris
- Comedones present
- No Telangiectasis
- No eye symptoms or signs
- Steroid-induced Acne
- Results from Corticosteroid use on face
- Perioral changes
-
Perioral Dermatitis
- Some dermatologists consider Perioral Dermatitis a variant of Rosacea
- Polymorphous Light Eruption or other Photodermatitis
- Seborrheic Dermatitis
- Contact Dermatitis
- Polymyositis
- Sarcoidosis
- Systemic Lupus Erythematosus
- Carcinoid Syndrome (severe facial Flushing)
- Mastocytosis
X. Differential Diagnosis: Ocular Rosacea
- Blepharokeratoconjunctivitis (staphylococcal or seborrheic)
- Sebaceous Gland carcinoma
- Allergic Conjunctivitis
XI. Diagnosis
- Central face dermatitis with at least one of the following findings
- Transient erythema (Flushing)
- Nontransient erythema
- Papules and Pustules
- Telangiectasia
XII. Management: General Measures
- Avoid triggers
- Avoid Alcohol
- Avoid prolonged heat exposure
- Avoid hot liquids (coffee, tea)
- Avoid heavy cosmetics
- Use sun screen (minimum SPF 30) regularly (better tolerated agents are listed)
- Avoid chemical Sunscreens which may be irritating
- Use a mineral or physical Sunscreen
- Base: Simethicone, dimethicone or cyclomethicone
- Active ingredient: Titanium Dioxide or Zinc Oxide
- Choose gentle skin care products
- Clear and free (dye and perfume free) products
- Mild cleansers with near neutral pH (e.g. cetaphil, dove sensitive skin)
- Skin Moisturizers (Emollients) applied to moist skin
- Avoid abrasive skin products
- Green or yellow tinted consmetics may hide facial erythema
- Avoid provocative medications
- Benzoyl Peroxide (avoid in erythematotelangiectatic Rosacea - subtype 1)
- Topical Corticosteroids
XIII. Management: Papular and pustular Rosacea
- Step 1
- Apply across entire central face
- First Line agents (most effective agents)
- Metronidazole topical
- Once daily (1% gel) or twice daily (0.75% gel, cream or lotion)
- Effective in 80% of cases
- Similar efficacy between 0.75% and 1%, as well as between once and twice daily dosing
- Azelaic Acid (Azelex) 15% gel
- Slight benefit over Metrogel, but less tolerated (consider in those not responding to Metronidazole)
- Gel is generic, while cream and foam are trade name only at twice the price
- Irritation may be reduced with gentle skin cleansers (e.g. cetaphil) and Skin Lubricants (e.g. vanicream)
- Elewski (2003) Arch Dermatol 139:1444-50 [PubMed]
- Metronidazole topical
- Alternative agents
- Clindamycin (Cleocin-T)
- Sulfacetamide/Sulfur (10%/5%) cream, foam or lotion
- Permethrin 5% cream
- Effective for erythema and Papules (but not as effective with Pustules)
- Kocak (2002) Dermatology 205:265-70 [PubMed]
- Step 2: May use the following oral agents in combination with topicals listed above
- Doxycyline (preferred)
- Moderate Rosacea
- Doxycyline 40 mg daily or 20 mg twice daily (sub-antimicrobial dose)
- Severe Rosacea or refractory to 8-12 weeks at lower dose Doxycycline
- Doxycycline 100 mg twice daily (then taper to once daily after the first month)
- Moderate Rosacea
- Alternative systemic antibiotics (tapering to once daily after the first month)
- Tetracycline 250 mg twice daily or
- Erythromycin 250 mg twice daily
- Amoxicillin 250 mg twice daily
- Efficacy
- Useful in treating Blepharitis, Keratitis
- Most effective treatment
- Doxycyline (preferred)
- Step 3: Additional topical agents to consider
- Erythema (without Papules or Pustules)
- Brimonidine gel 0.33% (Mirvaso) - see below
- Oxymetazoline 1% (Rhofade) - see below
- Inflammatory papular and pustular Rosacea
- Precaution: Avoid in erythematotelangiectatic Rosacea (Flushing) - subtype 1 (may worsen)
- Topical Benzoyl Peroxide with Clindamycin (e.g. Benzaclin)
- Avoid Benzyl Peroxide with Erythromycin (no benefit to the Erythromycin)
- Ivermectin (Scolantra) 1% cream applied once daily
- Very expensive (nearly $500 for 45 grams)
- (2015) Presc Lett 22(3): 16
- Minocycline 1.5% Foam (Zilxi)
- Very expensive (nearly $500 for 30 grams)
- No evidence of benefit over other Rosacea topicals
- (2021) Presc Lett 28(6): 36
- Erythema (without Papules or Pustules)
- Step 4: Refractory Cases
- Topical Tretinoin (Retin A)
- May exacerbate erythema and Telangiectasis
- Accutane for 20 weeks
- Variably effective
- Consider mite or tinea management
- Examine sample with Potassium Hydroxide
- Crotamiton (Eurax)
- Topical Tretinoin (Retin A)
XIV. Management: Associated conditions
- Facial Flushing and Erythema
- First-line: See general measures above
- Second-line
- See Vasomotor Symptoms of Menopause
- Clonidine 0.05 mg bid
- Propranolol (Inderal LA) 80 mg orally daily
- Topical vasconstrictors (onset of action 4 hours, duration 12 hours)
- Brimonidine gel 0.33% (Mirvaso)
- Topical Vasoconstrictor released in 2013 in U.S.
- Can reduce facial redness (NNT 6 for significant benefit)
- Very expensive ($400 for 30 grams)
- Consider using generic Brimonidine 0.2% eye drops topically on face (10% of cost)
- (2013) Presc Lett 20(11): 65
- Oxymetazoline 1% (Rhofade)
- Topical Vasoconstrictor released in 2017 in U.S. (same ingredient as Afrin 0.05%, but 1%)
- Very expensive ($475 for 30 grams)
- (2017) Presc Lett 24(5):30
- Brimonidine gel 0.33% (Mirvaso)
-
Telangiectasis
- Green-tinted cosmetics
- Pulsed dye laser
- Ocular changes
- Precautions
- Risk of complications such as Chalazion, Scleritis, Corneal Ulcer
- Consider ophthalmology Consultation
- First-line therapy
- Oral Doxycycline (or other oral antibiotics listed above)
- Artificial tears for eye dryness
- Lid and lashes cleansing with baby Shampoo
- Topical metrogel to Eyelid if involved
- Omega-3 Fatty Acid Supplementation
- Second-line therapy for refractory cases
- Ocular steroids (by ophthalmology)
- Cyclosporine Ophthalmic Emulsion (Restasis) - by ophthalmology
- Accutane
- References
- Precautions
- Rhinophyma
- Mild to moderate
- Antibiotics such as Doxycycline (as listed above)
- Oral Isotretinoin (Accutane)
- Advanced cases (Surgery)
- Dermabrasion
- Hypertrophic tissue excision
- Mild to moderate
XV. References
- (2021) Presc Lett 28(6): 36
- Habif (1996) Clinical Dermatology, p. 182-4
- Blount (2002) Am Fam Physician 66(3):435-40 [PubMed]
- Goldgar (2009) Am Fam Physician 80(5): 461-8 [PubMed]
- Oge (2015) Am Fam Physician 92(3): 187-96 [PubMed]
- Powell (2005) N Engl J Med 352(8):793-803 [PubMed]
- Zuber (2000) Prim Care 27(2):309-18 [PubMed]